# To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

> **NCT03915769** · PHASE3 · COMPLETED · sponsor: **Celgene** · enrollment: 198 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** Ozanimod
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03915769
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-03
- **Primary completion:** 2025-09-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 198 (ACTUAL)
- **Last updated:** 2025-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03915769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03915769, "To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03915769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*